Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Pharmacogenetics - 1 Dec 2001

Kidd R S, Curry T B, Gallagher S, Edeki T, Blaisdell J, Goldstein J A

Abstract excerpt

Cytochrome P450 (CYP) 2C9 is the principal enzyme responsible for the metabolism of numerous clinically important drugs. Two polymorphic alleles CYP2C9*2 and CYP2C9*3 have been documented which affect the metabolism and clinical toxicity of drugs such as phenytoin, warfarin, glipizide, and tolbut...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticonvulsants
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolic Clearance Rate

Share to Phenytoin

Share to Seizures

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11740344
DOI: 10.1097/00008571-200112000-00008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11740344-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.PMID 11740344Read ↗

Discovery of new potentially defective alleles of human CYP2C9.Semantic proximity Read ↗

Identification and functional characterization of new potentially defective alleles of human CYP2C19.Semantic proximity Read ↗

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)-Warfarin.Semantic proximity Read ↗

CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Semantic proximity Read ↗

Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.Semantic proximity Read ↗

Genetic analysis of the human cytochrome P450 CYP2C9 locus.Semantic proximity Read ↗

A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.Semantic proximity Read ↗

Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.Semantic proximity Read ↗

Identification of a novel variant CYP2C9 allele in Chinese.Semantic proximity Read ↗

In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.Semantic proximity Read ↗

Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.